Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT03139370
Title Safety and Efficacy of MAGE-A3/A6 T Cell Receptor Engineered T Cells (KITE-718) in HLA-DPB1*04:01 Positive Adults With Advanced Cancers
Recruitment Active, not recruiting
Gender both
Phase Phase I
Variant Requirements No
Sponsors Kite, A Gilead Company
Indications

Advanced Solid Tumor

Therapies

Cyclophosphamide + Fludarabine

KITE-718

Age Groups: senior | adult
Covered Countries USA


No variant requirements are available.